Pieris Pharmaceuticals (NASDAQ:PIRS) posted its earnings results on Thursday. The biotechnology company reported $0.00 EPS for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.01), Zacks Earnings Dates reports. The firm had revenue of $11.69 million for the quarter, compared to analysts’ expectations of $13.46 million. Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%.

Shares of NASDAQ:PIRS traded up $0.26 on Friday, hitting $5.68. The company had a trading volume of 778,350 shares, compared to its average volume of 517,590. Pieris Pharmaceuticals has a 52-week low of $4.41 and a 52-week high of $9.75. The company has a market capitalization of $286.14 million, a P/E ratio of -14.20 and a beta of 1.66.

PIRS has been the topic of several recent research reports. Cowen initiated coverage on Pieris Pharmaceuticals in a research report on Friday, May 4th. They issued an “outperform” rating on the stock. BidaskClub upgraded Pieris Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 26th. HC Wainwright set a $12.00 price objective on Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, June 7th. Finally, ValuEngine upgraded Pieris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $12.33.

In other Pieris Pharmaceuticals news, Director James A. Geraghty bought 10,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Tuesday, May 15th. The shares were purchased at an average cost of $5.75 per share, for a total transaction of $57,500.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at approximately $115,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.07% of the stock is owned by corporate insiders.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Recommended Story: How are Outstanding Shares Different from Authorized Shares?

Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.